8 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
GSK GlaxoSmithKline PLC $39.21 $97.25B Buy
Article Searches
Top Ranked Growth Stocks to Buy for February 15th http://www.zacks.com/commentary/213938/top-ranked-growth-stocks-to-buy-for-february-15th?cid=CS-ZC-FT-213938 Feb 15, 2019 - Top Ranked Growth Stocks to Buy for February 15th
GlaxoSmithKline: The Next Portfolio Vaccine? https://seekingalpha.com/article/4241365-glaxosmithkline-next-portfolio-vaccine?source=feed Feb 15, 2019 - Favorable Q4 figures bring out optimism amongst investors.New acquisitions and a new joint venture with Pfizer could lead to something huge.Higher-than-average yield also comes with its share of uncer
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B http://www.zacks.com/stock/news/354868/johnson-johnson-jnj-to-acquire-auris-health-for-%2434b?cid=CS-ZC-FT-354868 Feb 14, 2019 - Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
Top Ranked Income Stocks to Buy for February 14th http://www.zacks.com/commentary/213612/top-ranked-income-stocks-to-buy-for-february-14th?cid=CS-ZC-FT-213612 Feb 14, 2019 - Top Ranked Income Stocks to Buy for February 14th
New Strong Buy Stocks for February 14th http://www.zacks.com/commentary/213348/new-strong-buy-stocks-for-february-14th?cid=CS-ZC-FT-213348 Feb 14, 2019 - New Strong Buy Stocks for February 14th
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales http://www.zacks.com/stock/news/354603/astrazenecas-azn-q4-earnings-beat-new-drugs-drive-sales?cid=CS-ZC-FT-354603 Feb 14, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer http://www.zacks.com/stock/news/353843/mercks-keytruda-gets-fda-priority-review-for-head-neck-cancer?cid=CS-ZC-FT-353843 Feb 12, 2019 - Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Acer Therapeutics: Multiple Aces Up Its Sleeve https://seekingalpha.com/article/4240028-acer-therapeutics-multiple-aces-sleeve?source=feed_sector_healthcare Feb 11, 2019 - Acer announced on December 26, 2018 that the FDA had accepted Acer's NDA for EDSIVO for review for the treatment of vEDS.The FDA also granted priority review of the EDSIVO NDA with a PDUFA target acti

Pages: 1

Page 1

Related Companies

Name Exchange Price Mkt Cap
AZN Astrazeneca PLC NYSE $37.56 $95.16B
BMY Bristol-Myers Squibb Company NYSE $61.3 $100.03B
SNY Sanofi NYSE $43.75 $109.14B
LLY Eli Lilly and Company NYSE $105.71 $113.53B
NVO Novo Nordisk A/S NYSE $47.64 $114.84B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for GlaxoSmithKline PLC
GSK - Google Finance https://www.google.com/finance?q=GSK Industry related info and international coverage Summary News
GSK - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=GSK Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options